on November 5, 2012 |
Permalink
Topics: Readmissions, Quality, Performance Improvement, Medical Cardiology, Cardiovascular, Service Lines
Nicole MacMillan, Cardiovascular Roundtable
The Roundtable frequently receives questions related to heart failure clinics and cross-continuum care for this challenging and growing population. In light of HF readmission penalties beginning in October of this year, there is a clear focus among providers on lowering heart failure readmission rates to avoid paying fines of up to 1% of their base Medicare reimbursements. We have previously discussed the readmission penalty program and how to risk stratify heart failure patients to allocate post-discharge services appropriately.
Continue reading:
Planning and operating a heart failure clinic
on September 21, 2012 |
Permalink
Topics: Medical Cardiology, Cardiovascular, Service Lines, Risk Stratification, Methodologies, Performance Improvement, Readmissions, Quality
Nicole MacMillan, Cardiovascular Roundtable
The Roundtable frequently receives questions related to stratifying heart failure patients by risk of readmission, and about the various models and methods of implementation we have come across.
In light of impending HF readmission penalties beginning in October of this year, there is a clear focus among providers on lowering heart failure readmission rates to avoid paying fines of up to 1% of their base Medicare reimbursements. We have previously discussed the readmission penalty program.
Continue reading:
Risk stratification methods to reduce heart failure readmissions
on September 4, 2012 |
Permalink
Topics: Medical Cardiology, Cardiovascular, Service Lines, Stroke, Electrophysiology
Nicole MacMillan, Cardiovascular Roundtable
The introduction of novel oral anticoagulants to reduce the risk of stroke and systemic embolism in atrial fibrillation (AF) patients was hotly anticipated when the first of three new drugs hit the market in October 2010, and continues to be a frequent topic of discussion in industry journals and newsletters. While the Roundtable has covered the introduction of these new drugs in the past, we wanted to provide a more comprehensive overview of the current state of affairs, as well as what these new drugs could mean for those treating AF.
The three novel oral anticoagulants, dabigatran (Pradaxa, Boehringer Ingelheim), rivaroxaban (Xarelto, Bayer/ Johnson & Johnson) and apixaban (Eliquis, Pfizer/ Bristol-Myers Squibb), have been expected to revolutionize stroke prevention in AF patients, offering physicians the chance to take AF patients off warfarin.
Continue reading:
What’s going on with novel oral anticoagulants for AF?
